A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Multiple Myeloma

In brief

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Key facts

Study ID

NCT03989414

Run by

Celgene

People needed

424

Starts

2019-09-30

Expected to finish

2026-11-30

Last updated by the study team

2024-11-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
• For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:
• Documented diagnosis of multiple myeloma (MM) and measurable disease
• Documented disease progression during or after their last antimyeloma regimen
• Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen

You may not qualify if…

• Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis
• Known central nervous system (CNS) involvement with myeloma
• Received immunosuppressive medication within the last 14 days of initiating study treatment
• Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 119 — Denver, Colorado, United States
• Local Institution - 104 — Tampa, Florida, United States
• Local Institution - 108 — Atlanta, Georgia, United States
• Local Institution - 112 — Chicago, Illinois, United States
• Local Institution - 107 — Chicago, Illinois, United States
• Local Institution - 117 — Boston, Massachusetts, United States
• Local Institution - 101 — Boston, Massachusetts, United States
• Local Institution - 118 — Boston, Massachusetts, United States
• Local Institution - 113 — Detroit, Michigan, United States
• Local Institution - 106 — Rochester, Minnesota, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Local Institution - 110 — Winston-Salem, North Carolina, United States
• Local Institution - 115 — Columbus, Ohio, United States
• Local Institution - 114 — Nashville, Tennessee, United States
• Local Institution - 116 — Houston, Texas, United States
• Swedish Cancer Institute — Seattle, Washington, United States
• Local Institution - 201 — Calgary, Alberta, Canada
• Local Institution - 205 — Edmonton, Alberta, Canada
• Local Institution - 204 — Halifax, Nova Scotia, Canada
• Local Institution - 203 — Toronto, Ontario, Canada
• Local Institution - 202 — Montreal, Quebec, Canada
• Local Institution - 802 — Brno, Czechia
• Local Institution - 801 — Ostrava-Poruba, Czechia
• Local Institution - 803 — Prague, Czechia
• Local Institution - 902 — Odense, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.